ArticleTransplant international : official journal of the European Society for Organ Transplantation2023
European Society of Organ Transplantation (ESOT) Consensus Report on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 31 citations in OpenAlex.
- Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma.Hepatic oncology · 2026Review
- Future surgical strategies for hepatocellular carcinoma in Italy: a strategic framework and scenario-based projection of liver transplantation and hepatic resection from 2027 onwards.Updates in surgery · 2026Article
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- Article
- Post-Transplant HCC Recurrence and Survival: Impact of Bridging Therapy and Tumor Biology in 185 Consecutive Liver Transplants.Journal of clinical medicine · 2026Article
- Refining prognostication in intermediate-stage hepatocellular carcinoma after transarterial chemoembolization: promise and limitations of the proposed NTAA model.Hepatobiliary surgery and nutrition · 2026Article
- Publication Trends of Research on Immune Tolerance After Kidney Transplantation: A Bibliometric Analysis from 1976 to 2024.Journal of multidisciplinary healthcare · 2026Article
- The Top 12 Most Impactful Papers in Clinical Transplantation in 2025: TI Editors' Choice.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- The role of immunotherapy prior to liver transplantation in advanced or down-staged HCC - timing of transplants, selection of patients, and hurdles to overcome with immunosuppression.International journal of surgery (London, England) · 2026Review
- Feasibility and Effectiveness of Liver Transplantation following Immunotherapy in Patients with Hepatocellular Carcinoma.Liver cancer · 2025Article
- Review
- New Scenarios in Liver Transplantation for Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma.NPJ precision oncology · 2025Review
- Integrating CT Radiomics and Clinical Features to Optimize TACE Technique Decision-Making in Hepatocellular Carcinoma.Cancers · 2025Article
- Overall survival is comparable between percutaneous radiofrequency ablation and liver resection as first-line therapies for solitary 3-5 cm hepatocellular carcinoma.Langenbeck's archives of surgery · 2025Article
- The role of radiological interventions in hepatocellular carcinoma before liver transplantation: a surgical perspective.Frontiers in surgery · 2025Review
- Review
- Outcomes of Bridging Therapy in Liver Transplantation for Hepatocellular Carcinoma.Journal of clinical medicine · 2024Article
- Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver.International journal of molecular sciences · 2024Review
- Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma.Expert review of gastroenterology & hepatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver transplantation offers the best chance of cure for most patients with non-metastatic hepatocellular carcinoma (HCC). Although not all patients with HCC are eligible for liver transplantation at diagnosis, some can be downstaged using locoregional treatments such as ablation and transarterial chemoembolization. These aforementioned treatments are being applied as bridging therapies to keep patients within transplant criteria and to avoid them from dropping out of the waiting list while awaiting a liver transplant. Moreover, immunotherapy might have great potential to support downstaging and bridging therapies. To address the contemporary status of downstaging, bridging, and immunotherapy in liver transplantation for HCC, European Society of Organ Transplantation (ESOT) convened a dedicated working group comprised of experts in the treatment of HCC to review literature and to develop guidelines pertaining to this cause that were subsequently discussed and voted during the Transplant Learning Journey (TLJ) 3.0 Consensus Conference that took place in person in Prague. The findings and recommendations of the working group on Downstaging, Bridging and Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma are presented in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.